医学信息2025，Vol.38Issue(7)：1-9,9.DOI:10.3969/j.issn.1006-1959.2025.07.001
巨噬细胞M2标志物CD163和MRC1在急性髓性白血病中的预后分析
Prognostic Analysis of Macrophage M2 Markers CD163 and MRC1 in Acute Myeloid Leukemia
摘要
Abstract
Objective To investigate the effect of the expression of tumor-associated macrophage M2(M2-TAMs)markers CD163 and MRC1 on the survival and prognosis of acute myeloid leukemia(AML).Methods Pan-cancer analysis of CD163 and MRC1 was performed by TCGA and UALCAN.TARGET,GEPIA2,UALCAN,Kaplan-Meier Plotter and Oncolnc databases were used to analyze the differential expression and survival prognosis of CD163 and MRC1 in AML.The TISCH database was used to analyze CD163 and MRC1 at the single cell level.Results The expression of MRC1 was down-regulated in most tumor tissues,and the expression of CD163 in tumor tissues was higher than that in adjacent tissues(P<0.05).By searching TCGA,TARGET,GEPIA2,UALCAN,Kaplan-Meier Plotter and Oncolnc databases,it was found that the survival time of AML patients with high expression of CD163 and MRC1 was shorter than that of low expression group,which was a high risk factor,and the difference was statistically significant(P<0.05).In the single cell data set AML_GSE116256,it was found that CD163 was mainly expressed in mononuclear macrophages,MRC1 was mainly expressed in mononuclear macrophages,NK cells and malignant cells,and the successful induction of polarized M2-TAMs was verified by cell morphological observation and immunofluorescence.Conclusion Compared with healthy controls,patients with AML have high expression of CD163 and MRC1,and patients with high M2-TAMs infiltration have a poor prognosis.CD163 and MRC1 were preliminarily demonstrated as potential prognostic indicators in AML.关键词
急性髓系白血病/肿瘤相关巨噬细胞M2/CD163/MRC1Key words
Acute myeloid leukemia/M2-tumor-associated macrophages/CD163/MRC1分类
临床医学引用本文复制引用
冯小云,卓英权,秦玉凤,卢茜,袁月,彭美林,李丹,王岚,张鹏..巨噬细胞M2标志物CD163和MRC1在急性髓性白血病中的预后分析[J].医学信息,2025,38(7):1-9,9.基金项目
1.国家自然科学基金地区科学基金项目(编号:81960036) （编号:81960036）
2.贵州省科技计划项目(编号:黔科合基础-ZK[2021]重点005). （编号:黔科合基础-ZK[2021]重点005）
